Company Profile

Intercytex is the leading developer of innovative regenerative medicine products. 

Intercytex uses its fully integrated cell technology platform to develop living, human cell-based  products, at commercially viable scale in attractive markets.

Intercytex has four products in development:

• VAVELTA®, a skin repair and rejuvenation product intended to improve the feel, function and appearance of skin damaged by scarring and the aging process, commercially available from a number of accredited centres in the UK 

• SHEF-1, development of a stem cell line suitable for differentiation into retinal pigment epithelial (RPE) cells, being carried out in collaboration with the London Project to Cure Blindness

• ICX-SKN, being developed as a skin graft replacement for burns and acute wounds, Phase I trials completed

• ICX-TRC, a hair regeneration product, in Phase II trials.
  

All Intercytex' products are derived from unmodified human cells.

Intercytex commenced operations in 2000 and currently employs around 50 staff. In addition to its head office in Cambridge, UK, it has its own GMP compliant clinical production facility plus research and development laboratories in Manchester, UK and a dedicated stem cell research laboratory in Sheffield, UK. Additional laboratories are located in Boston, US.

Intercytex’ shares trade on the Alternative Investment Market of the London Stock Exchange under the ticker symbol ICX.L.